Selective PPAR agonists for the treatment of type 2 diabetes

Annals of the New York Academy of Sciences

Volumn 1067, Issue 1, 2006, Pages 448-453

  Nehlin, Jan O ^a,b   Mogensen, John P ^a   Petterson, Ingrid ^a   Jeppesen, Lone ^a   Fleckner, Jan ^a   Wulff, Erik M ^a   Sauerberg, Per ^a  

^a NOVO NORDISK A S   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Diabetes type 2; Dyslipidemia; Hyperglycemia; Insulin sensitizers; PPAR; Triple agonists

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN SENSITIZING AGENT; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA,GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA,GAMMA,DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RAGAGLITAZAR; ROSIGLITAZONE; UNCLASSIFIED DRUG;

CHRONIC DISEASE; CONFERENCE PAPER; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG POTENCY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIGAND BINDING; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANIMALIA;

EID: 33744503414     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1354.064     Document Type: Conference Paper

References (23)

1. World Health Organisation. 2005. http://www.who.int/en/.
2. Wild, S. et al. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 : 1047 1053.
3. Stumvoll, M., B.J. Goldstein & T.W. Van Haeften. 2005. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 : 1333 1346.
4. Etgen, G.H. & N. Mantlo. 2003. PPAR ligands for metabolic disorders. Curr. Top. Med. Chem. 3 : 1649 1661.
5. Willson, T.M. et al. 1996. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 39 : 665 668.
6. Evans, R.M., G.D. Barish & Y.X. Wang. 2004. PPARs and the complex journey to obesity. Nat. Med. 10 : 355 361.
7. Ferre, P. 2004. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 Suppl 1 S43 S50.
8. Berger, J.P., T.E. Akiyama & P.T. Meinke. 2005. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26 : 244 251.
9. Van Raalte, D.H. et al. 2004. Peroxisome proliferator-activated receptor (PPAR)-alpha: a (PPAR)-alpha: a pharmacological target with a promising future. Pharm. Res. 21 : 1531 1538.
10. Rangwala, S.M. & M.A. Lazar. 2004. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol. Sci. 25 : 331 336.
11. Rosen, E.D. & B.M. Spiegelman. 2001. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276 : 37731 37734.
12. Fredenrich, A. & P.A. Grimaldi. 2005. PPARdelta: an incompletely known PPAR nuclear receptor. Diabetes Metab. 31 : 23 27.
13. Oliver, W.R. et al. 2001. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci.USA 98 : 5306 5311.
14. Forman, B.M. et al. 1995. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83 : 803 812.
15. Kliewer, S.A. et al. 1995. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83 : 813 819.
16. Fu, J. et al. 2003. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425 : 90 93.
17. Lo Verme, J. et al. 2004. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67 : 15 19.
18. English, P. & G. Williams. 2001. Type 2 diabetes. Martin Dunitz Ltd. Taylor & Francis, London.
19. Sauerberg, P. et al. 2002. Novel tricyclic-α- alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. J. Med. Chem. 45 : 789 804.
20. Mogensen, J.P. et al. 2003. Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template. Bioorg. Med. Chem. Lett. 13 : 257 260.
21. Lohray, B.B. et al. 2001. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J. Med. Chem. 44 : 2675 2678.
22. Sauerberg, P. et al. 2003. Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo. J. Med. Chem. 46 : 4883 4894.
23. Sauerberg, P. et al. 2005. Structure-activity relationships of dimeric PPAR agonists. Bioorg. Med. Chem. Lett. 15 : 1497 1500.